Cargando…

Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer

Background: Whole pelvic radiotherapy (WPRT) with stereotactic body radiotherapy (SBRT) boost has been shown to be effective in patients with high-risk prostate cancer (PC). However, no study has directly compared the efficacy of WPRT with SBRT boost with that of conventionally fractionated radiothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shih-Chang, Ting, Wei-Chen, Chang, Yun-Ching, Yang, Ching-Chieh, Lin, Li-Ching, Ho, Hsiu-Wen, Chu, Shou-Sheng, Lin, Yu-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273130/ https://www.ncbi.nlm.nih.gov/pubmed/32547949 http://dx.doi.org/10.3389/fonc.2020.00814

Ejemplares similares

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer
por: Lin, Yu-Wei, et al.
Publicado: (2014)

A focused very high energy electron beam for fractionated stereotactic radiotherapy
por: Svendsen, Kristoffer, et al.
Publicado: (2021)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

A comparison between high dose rate brachytherapy and stereotactic body radiotherapy boost after elective pelvic irradiation for high and very high-risk prostate cancer
por: Novikov, Sergey Nikolaevich, et al.
Publicado: (2022)

The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung
por: Bilski, Mateusz, et al.
Publicado: (2021)

Doses, fractionations, constraints for stereotactic radiotherapy
por: Borghesi, Simona, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis
por: Yang, Jen-Fu, et al.
Publicado: (2019)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
por: Kim, Hun Jung, et al.
Publicado: (2015)

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung
por: Wegner, Rodney E, et al.
Publicado: (2020)

A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer
por: Wang, Fang, et al.
Publicado: (2023)

Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis
por: Dong, Jinling, et al.
Publicado: (2021)

Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas
por: Elhateer, H., et al.
Publicado: (2008)

Fractionated stereotactic radiotherapy for pediatric patients with retinoblastoma
por: Higgins, Patrick D., et al.
Publicado: (2006)

Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy
por: Vasudevan, Harish N., et al.
Publicado: (2017)

The Quest for Optimal Fractionation Schedules in Stereotactic Radiotherapy
por: Shibamoto, Yuta, et al.
Publicado: (2020)

Simple immobilization for stereotactic radiotherapy aimed at pelvic metastases
por: Janssen, Jorinde, et al.
Publicado: (2023)

Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2023)

A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma
por: Huang, Chun-Ming, et al.
Publicado: (2017)

Compared with intensity‐modulated radiotherapy, image‐guided radiotherapy reduces severity of acute radiation‐induced skin toxicity during radiotherapy in patients with breast cancer
por: Lin, Jang‐Chun, et al.
Publicado: (2018)

A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer
por: Li, Can, et al.
Publicado: (2020)

Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer †
por: Poon, Darren M. C., et al.
Publicado: (2021)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Comparison of long-term survival and toxicity of simultaneous integrated boost vs conventional fractionation with intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma
por: Tao, Hengmin, et al.
Publicado: (2016)

On the Immunological Consequences of Conventionally Fractionated Radiotherapy
por: Alfonso, Juan Carlos L., et al.
Publicado: (2020)

Extracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas
por: Ram, Thomas Samuel, et al.
Publicado: (2006)

Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies
por: Kim, Yeon Joo, et al.
Publicado: (2018)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States
por: P. Weiner, Joseph, et al.
Publicado: (2017)

Effective salvage of recurrent craniopharyngioma with fractionated stereotactic radiotherapy
por: Burgess, Laura, et al.
Publicado: (2020)

Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma
por: Combs, Stephanie E, et al.
Publicado: (2007)

Comparative Study of Hypo-Fractionated Radiotherapy Versus Conventional Radiotherapy in Breast Cancer
por: Narwariya, Abhinav, et al.
Publicado: (2022)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
por: Ma, Ting Martin, et al.
Publicado: (2020)

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma
por: Liu, Feng, et al.
Publicado: (2013)

High-dose stereotactic radiotherapy boost in the treatment of squamous cell carcinoma of the head and neck region
por: Polanowski, Paweł, et al.
Publicado: (2022)

Stereotactic Radiotherapy for Oligometastasis
por: Otake, Sotaro, et al.
Publicado: (2019)

Radiobiology of stereotactic radiotherapy
por: Mangoni, Monica, et al.
Publicado: (2022)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
por: Lee, Tae Hoon, et al.
Publicado: (2021)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
por: Clarke, Eleanor, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sf85fpnsu5n4ldl9qbukrt15m8